Month: December 2021

We close a 2021 full of science!

When the year ends it is a good time to look back and review the challenges achieved in the last twelve months. More than 1,300 scientific articles, of which 550 are led by IDIBELL, show that there many objectives have been achieved, but there are also many questions that remain to be answered.

Immunotherapy with genetically modified immune cells increases survival of patients with aggressive B lymphoma who do not respond to chemotherapy

Two studies published in The New England Journal of Medicine, with the participation of IDIBELL and the ICO, present the results of two phase 3 clinical trials comparing treatment with CART lymphocytes versus conventional treatment with chemotherapy and bone marrow transplantation.

The DACMA Association donates 8,000 euros for breast cancer research

The Association of Women with Breast Cancer (DACMA) has donated a check for 8,000 euros to IDIBELl and ICO dedicated to breast cancer research. This donation counted on the participation of Belén García, the mayor of Sant Joan Despí, where DACMA has its headquarters, who wanted to accompany the entity members in this event.

From lab to market: the fourth edition of the Accelerator Meeting Point promotes Bellvitge’s biomedical innovation

The most innovative projects in the healthcare and biomedical sector were presented on December the 16th at the fourth edition of the Accelerator Meeting Point (AMP), organized by the Business Development and Innovation Area of ​​the Biomedical Research Institute of Bellvitge (IDIBELL). The fourth edition of the AMP has counted on the participation of AIISEM, …

From lab to market: the fourth edition of the Accelerator Meeting Point promotes Bellvitge’s biomedical innovation Read More »

Scroll to Top